tetano
Editor, Senior Moderator
Signal Transduct Target Ther
. 2022 May 17;7(1):159.
doi: 10.1038/s41392-022-01002-1.
Intranasal administration of a recombinant RBD vaccine induces long-term immunity against Omicron-included SARS-CoV-2 variants
Hong Lei[SUP] #[/SUP][SUP] 1 [/SUP], Aqu Alu[SUP] #[/SUP][SUP] 1 [/SUP], Jingyun Yang[SUP] #[/SUP][SUP] 1 [/SUP], Wenyan Ren[SUP] 1 [/SUP], Cai He[SUP] 1 [/SUP], Tianxia Lan[SUP] 1 [/SUP], Xuemei He[SUP] 1 [/SUP], Li Yang[SUP] 1 2 [/SUP], Jiong Li[SUP] 1 2 [/SUP], Zhenling Wang[SUP] 1 2 [/SUP], Xiangrong Song[SUP] 1 2 [/SUP], Wei Wang[SUP] 1 2 [/SUP], Guangwen Lu[SUP] 3 4 [/SUP], Xiawei Wei[SUP] 5 6 [/SUP]
Affiliations
Abstract
The outbreak of coronavirus disease 2019 (COVID-19) has posed great threats to global health and economy. Several effective vaccines are available now, but additional booster immunization is required to retain or increase the immune responses owing to waning immunity and the emergency of new variant strains. The deficiency of intramuscularly delivered vaccines to induce mucosal immunity urged the development of mucosal vaccines. Here, we developed an adjuvanted intranasal RBD vaccine and monitored its long-term immunogenicity against both wild-type and mutant strains of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), including Omicron variants, in mice. Three-dose intranasal immunization with this vaccine induced and maintained high levels of neutralizing IgG antibodies in the sera for at least 1 year. Strong mucosal immunity was also provoked, including mucosal secretory IgA and lung-resident memory T cells (T[SUB]RM[/SUB]). We also demonstrated that the long-term persistence of lung T[SUB]RM[/SUB] cells is a consequence of local T-cell proliferation, rather than T-cell migration from lymph nodes. Our data suggested that the adjuvanted intranasal RBD vaccine is a promising vaccine candidate to establish robust, long-lasting, and broad protective immunity against SARS-CoV-2 both systemically and locally.
. 2022 May 17;7(1):159.
doi: 10.1038/s41392-022-01002-1.
Intranasal administration of a recombinant RBD vaccine induces long-term immunity against Omicron-included SARS-CoV-2 variants
Hong Lei[SUP] #[/SUP][SUP] 1 [/SUP], Aqu Alu[SUP] #[/SUP][SUP] 1 [/SUP], Jingyun Yang[SUP] #[/SUP][SUP] 1 [/SUP], Wenyan Ren[SUP] 1 [/SUP], Cai He[SUP] 1 [/SUP], Tianxia Lan[SUP] 1 [/SUP], Xuemei He[SUP] 1 [/SUP], Li Yang[SUP] 1 2 [/SUP], Jiong Li[SUP] 1 2 [/SUP], Zhenling Wang[SUP] 1 2 [/SUP], Xiangrong Song[SUP] 1 2 [/SUP], Wei Wang[SUP] 1 2 [/SUP], Guangwen Lu[SUP] 3 4 [/SUP], Xiawei Wei[SUP] 5 6 [/SUP]
Affiliations
- PMID: 35581200
- DOI: 10.1038/s41392-022-01002-1
Abstract
The outbreak of coronavirus disease 2019 (COVID-19) has posed great threats to global health and economy. Several effective vaccines are available now, but additional booster immunization is required to retain or increase the immune responses owing to waning immunity and the emergency of new variant strains. The deficiency of intramuscularly delivered vaccines to induce mucosal immunity urged the development of mucosal vaccines. Here, we developed an adjuvanted intranasal RBD vaccine and monitored its long-term immunogenicity against both wild-type and mutant strains of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), including Omicron variants, in mice. Three-dose intranasal immunization with this vaccine induced and maintained high levels of neutralizing IgG antibodies in the sera for at least 1 year. Strong mucosal immunity was also provoked, including mucosal secretory IgA and lung-resident memory T cells (T[SUB]RM[/SUB]). We also demonstrated that the long-term persistence of lung T[SUB]RM[/SUB] cells is a consequence of local T-cell proliferation, rather than T-cell migration from lymph nodes. Our data suggested that the adjuvanted intranasal RBD vaccine is a promising vaccine candidate to establish robust, long-lasting, and broad protective immunity against SARS-CoV-2 both systemically and locally.